XINGYA JIANG  Professor(PI)

  E-mail：

  xingyajiang@scut.edu.cn

2021—present  South China University of Technology,  Professor

2019—2021   Harvard Medical School,  Postdoctoral Research Fellow

2014—2019   The University of Texas at Dallas,  Ph.D.

2010—2014   Beijing Institute of Technology,  B.Sc.

(1)Nano-bio interaction

Toelucidate the mechanisms governing the in vivo transport, transformation, metabolism,and clearance of nanoparticles; and to develop strategies for preciselymodulating the in vivo fate of nanoparticles, aiming to enhance the efficacyand reduce the toxicity of nanomedicines.

(2)Molecular/Nanoprobes

Toaddress the demand for early detection of major diseases associated with theliver and kidneys, by developing renally metabolizable imaging probes andfluidic (body fluid) probes capable of recognizing early disease-relatedmolecular signals, thereby enabling sensitive, accurate, and convenient diseasediagnosis.

(3)Kidney-Targeted Nucleic Acid Therapeutics

Toaddress the pressing need for extrahepatic nucleic acid drug delivery andovercome the bottlenecks in renal drug delivery, by developing highlykidney-specific targeting strategies for nucleic acid delivery, with the goalof intervening in kidney diseases and associated metabolic disorders.

Lab website: https://www.x-mol.com/groups/ultranano

Prof. Xingya Jiang’s laboratory primarily employs methodologies from analytical chemistry, molecular biology,and bioimaging to investigate the interfacial interaction mechanisms betweennanoparticles and living organisms. We focus particularly on the interactionsof nanoparticles with organs and tissues such as the liver and kidneys, as wellas their in vivo transport, transformation, metabolism, and clearance processes. Our goal is to advance the fundamental understanding of how nanomaterials interact with the complex physiological environment in vivo,thereby guiding the design of nanomedicines that can more effectively overcome various physiological barriers while enhancing efficacy and reducing toxicity.Building on this knowledge, we further design and develop novel diagnostic and therapeutic tools for the early detection and effective intervention of major diseases.

Our research group is actively engaged in three major areas: in vivo nano-biointeraction, disease-detecting probes, and kidney-targeted drug delivery. Our achievements include elucidating the biotransformation pathways of gold nanoparticles in the liver and kidneys, establishing strategies to modulate thein vivo biotransformation efficiency of gold nanoparticles, developing multiple approaches to promote hepatic metabolism of nanoparticles, and creating aseries of early-detection probes for liver/kidney injury as well askidney-targeted drug delivery technologies. Our research findings have been published as first/corresponding-author papers in internationally renownedacademic journals, including Nature Nanotechnology, Science Advances, NatureCommunications, Angewandte Chemie International Edition, ACS Nano, NanoLetters, and Nano Today, among others. We have been granted 7 China/US patents.Our research is supported by various funding sources, including the National Youth Talent Program, the General Program of the National Natural Science Foundation of China (NSFC), the Youth Program of the National Key Research andDevelopment Program of China, and the Guangzhou Basic and Applied BasicResearch Project, among others.